How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/iti-007-lumateperone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

ITI-007 (Lumateperone) — Competitive Intelligence Brief

ITI-007 (Lumateperone) (ITI-007 (Lumateperone)) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serotonin 5-HT7 receptor antagonist / Phosphodiesterase 1 inhibitor. Area: Psychiatry / Neurology.

phase 3 Serotonin 5-HT7 receptor antagonist / Phosphodiesterase 1 inhibitor 5-HT7 receptor, PDE1 Psychiatry / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

ITI-007 (Lumateperone) (ITI-007 (Lumateperone)) — Intra-Cellular Therapies, Inc.. Lumateperone is a serotonin 5-HT7 receptor antagonist and phosphodiesterase 1 inhibitor that modulates intracellular signaling pathways implicated in psychosis and mood disorders.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ITI-007 (Lumateperone) TARGET	ITI-007 (Lumateperone)	Intra-Cellular Therapies, Inc.	phase 3	Serotonin 5-HT7 receptor antagonist / Phosphodiesterase 1 inhibitor	5-HT7 receptor, PDE1
Lumateperone high dose	Lumateperone high dose	Intra-Cellular Therapies, Inc.	phase 3	5-HT7 receptor antagonist / PDE10 inhibitor	5-HT7 receptor, PDE10

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Serotonin 5-HT7 receptor antagonist / Phosphodiesterase 1 inhibitor class)

Intra-Cellular Therapies, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ITI-007 (Lumateperone) — Competitive Intelligence Brief. https://druglandscape.com/ci/iti-007-lumateperone. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab